Role of serum progranulin in type Ⅰ autoimmune hepatitis prognosis evaluation

doi:10.3969/j.issn.1673-8640.2023.03.008

Abstract

Abstract: Objective To investigate the expression of serum progranulin（PGRN） in the prognosis evaluation of patients with type Ⅰ autoimmune hepatitis（AIH）. Methods Totally，39 active type Ⅰ AIH patients were enrolled as AIH group，and 35 healthy subjects were enrolled as control group. The general data and the determination results of white blood cell（WBC） count，serum liver enzymes，immunoglobulins and autoantibodies were collected. Serum levels of PGRN，interleukin（IL）-17 and IL-10 were determined. The changes in serum PGRN before and after treatment and its correlation with recurrence were analyzed. Spearman correlation analysis was used to analyze the correlations of serum PGRN with IL-17，IL-10 and clinical parameters. Receiver operating characteristic （ROC） curve was used to evaluate the efficiency of serum PGRN in the diagnosis of type Ⅰ AIH recurrence. Results Compared with healthy control group，serum PGRN and IL-17 were increased in AIH group（P<0.05），while IL-10 was decreased（P<0.05）. Serum PGRN was positively correlated with IL-17，gamma-glutamyltransferase（GGT），immunoglobulin G（IgG） and immunoglobulin M（IgM）（r values were 0.410，0.489，0.596 and 0.525，P<0.05）. Serum PGRN level in AIH group after treatment was lower than that before treatment（P<0.01）. Serum PGRN was higher in recurrence patients than that in non-recurrence patients（P<0.05）. ROC curve results showed that the area under curve of serum PGRN was 0.78 for predicting type Ⅰ AIH recurrence. When the optimal cut-off value was 80.75 pg/mL，the sensitivity was 62.50%，and the specificity was 83.33%. Conclusions Serum PGRN is increased in type Ⅰ AIH patients，it is related to AIH treatment efficiency and recurrence，and it can be used as an indicator to evaluate liver inflammation，injury severity and recurrence.

Key words: Progranulin, Interleukin 17, Interleukin 10, Autoimmune hepatitis

CLC Number:

R446.1

REN Huirong, XU Tingjuan, WU Tao, HUANG Mei, YANG Liang. Role of serum progranulin in type Ⅰ autoimmune hepatitis prognosis evaluation[J]. Laboratory Medicine, 2023, 38(3): 245-250.

Figures/Tables 6

References 24

[1]	TANAKA A. Autoimmune hepatitis:2019 update[J]. Gut Liver, 2020, 14(4):430-438. DOI URL
[2]	KOMORI A. Recent updates on the management of autoimmune hepatitis[J]. Clin Mol Hepatol, 2021, 27(1):58-69. DOI PMID
[3]	UYANIK M, SERTOGLU E, KAYADIBI H. Early diagnosis of autoimmune hepatitis on the basis of demographic and biochemical parameters[J]. Eur J Gastroenterol Hepatol, 2014, 26(9):1060-1061.
[4]	LIBERAL R, MIELI-VERGANI G, VERGANI D. Autoimmune hepatitis:from mechanisms to therapy[J]. Rev Clin Esp(Barc), 2016, 216(7):372-383.
[5]	LIANG M, LIWEN Z, YUN Z, et al. The imbalance between Foxp3+Tregs and Th1/Th17/Th22 cells in patients with newly diagnosed autoimmune hepatitis[J]. J Immunol Res, 2018, 2018:3753081.
[6]	POGONOWSKA M, PONIATOWSKI Ł A, WAWRZYNIAK A, et al. The role of progranulin(PGRN) in the modulation of anti-inflammatory response in asthma[J]. Cent Eur J Immunol, 2019, 44(1):97-101.
[7]	JING C, ZHANG X, SONG Z, et al. Progranulin mediates proinflammatory responses in systemic lupus erythematosus:implications for the pathogenesis of systemic lupus erythematosus[J]. J Interferon Cytokine Res, 2020, 40(1):33-42. DOI URL
[8]	ALVAREZ F, BERG P A, BIANCHI F B, et al. International autoimmune hepatitis group report:review of criteria for diagnosis of autoimmune hepatitis[J]. J Hepatol, 1999, 31(5):929-938. DOI URL
[9]	TIAN G, JIN X, WANG Q, et al. Recent advances in the study of progranulin and its role in sepsis[J]. Int Immunopharmacol, 2020, 79:106090. DOI URL
[10]	WEI J, HETTINGHOUSE A, LIU C. The role of progranulin in arthritis[J]. Ann N Y Acad Sci, 2016, 1383(1):5-20. DOI URL
[11]	JIAN J, KONOPKA J, LIU C. Insights into the role of progranulin in immunity,infection,and inflammation[J]. J Leukoc Biol, 2013, 93(2):199-208. DOI URL
[12]	ARECHAVALETA-VELASCO F, PEREZ-JUAREZ C E, GERTON G L, et al. Progranulin and its biological effects in cancer[J]. Med Oncol, 2017, 34(12):194. DOI URL
[13]	WANG S, WEI J, FAN Y, et al. Progranulin is positively associated with intervertebral disc degeneration by interaction with IL-10 and IL-17 through TNF pathways[J]. Inflammation, 2018, 41(5):1852-1863. DOI PMID
[14]	LI L, LI L, XIAO L, et al. Progranulin ameliorates coxsackievirus-B3-induced viral myocarditis by downregulating Th1 and Th17 cells[J]. Exp Cell Res, 2018, 367(2):241-250. DOI PMID
[15]	WEI F, ZHANG Y, JIAN J, et al. PGRN protects against colitis progression in mice in an IL-10 and TNFR2 dependent manner[J]. Sci Rep, 2014, 4:7023. DOI PMID
[16]	ZHAO Y P, TIAN Q Y, LIU C J. Progranulin deficiency exaggerates,whereas progranulin-derived Atsttrin attenuates,severity of dermatitis in mice[J]. FEBS Lett, 2013, 587(12):1805-1810. DOI URL
[17]	WEI F, ZHANG Y, JIAN J, et al. PGRN protects against colitis progression in mice in an IL-10 and TNFR2 dependent manner[J]. Sci Rep, 2014, 4:7023. DOI PMID
[18]	WEI F, ZHANG Y, ZHAO W, et al. Progranulin facilitates conversion and function of regulatory T cells under inflammatory conditions[J]. PLoS One, 2014, 9(11):e112110. DOI URL
[19]	ZHAO Y P, LIU B, TIAN Q Y, et al. Progranulin protects against osteoarthritis through interacting with TNF-α and β-catenin signalling[J]. Ann Rheum Dis, 2015, 74(12):2244-2253. DOI URL
[20]	MATSUBARA T, MITA A, MINAMI K, et al. PGRN is a key adipokine mediating high fat diet-induced insulin resistance and obesity through IL-6 in adipose tissue[J]. Cell Metab, 2012, 15(1):38-50. DOI PMID
[21]	TANAKA A, TSUKAMOTO H, MITOMA H, et al. Serum progranulin levels are elevated in patients with systemic lupus erythematosus,reflecting disease activity[J]. Arthritis Res Ther, 2012, 14(6):R244. DOI URL
[22]	MONTANO-LOZA A J, CARPENTER H A, CZAJA A J. Consequences of treatment withdrawal in type 1 autoimmune hepatitis[J]. Liver Int, 2007, 27(4):507-515. DOI URL
[23]	CZAJA A J, MENON K V, CARPENTER H A. Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis:a retrospective analysis[J]. Hepatology, 2002, 35(4):890-897. DOI URL
[24]	JIAN J, LI G, HETTINGHOUSE A, et al. Progranulin:a key player in autoimmune diseases[J]. Cytokine, 2018, 101:48-55. DOI URL

组别	例数	WBC计数/（×10⁹/L）	ALT/（U/L）	AST/（U/L）	GGT/（U/L）	ALP/（U/L）
AIH组	39	7.51±3.83	142.5±101.2	137.3±58.1	189.2±63.7	175.3±39.2
正常对照组	35	5.13±3.80	22.8±7.9	21.9±6.1	25.4±6.8	91.3±24.2
统计值		2.314	17.898	16.562	20.365	6.237
P值		0.035	0.000	0.000	0.000	0.000

组别	例数	WBC计数/（×10⁹/L）	ALT/（U/L）	AST/（U/L）	GGT/（U/L）	ALP/（U/L）
AIH组	39	7.51±3.83	142.5±101.2	137.3±58.1	189.2±63.7	175.3±39.2
正常对照组	35	5.13±3.80	22.8±7.9	21.9±6.1	25.4±6.8	91.3±24.2
统计值		2.314	17.898	16.562	20.365	6.237
P值		0.035	0.000	0.000	0.000	0.000

组别	例数	PGRN/（ng/mL）	IL-10/（pg/mL）	IL-17/（pg/mL）
AIH组	39	72.35±12.92	5.37±2.80	13.52±6.78
正常对照组	35	33.04±9.26	17.21±6.99	2.89±0.54
t值		9.61	13.28	13.77
P值		0.000	0.000	0.000

组别	例数	PGRN/（ng/mL）	IL-10/（pg/mL）	IL-17/（pg/mL）
AIH组	39	72.35±12.92	5.37±2.80	13.52±6.78
正常对照组	35	33.04±9.26	17.21±6.99	2.89±0.54
t值		9.61	13.28	13.77
P值		0.000	0.000	0.000

组别	例数	PGRN/（ng/mL）	WBC计数/（×10⁹/L）	ALT/（U/L）	AST/（U/L）	GGT/（U/L）
治疗前	12	75.88±12.34	7.71±4.35	159.6±125.7	135.7±52.9	192.3±58.7
治疗后	12	52.47±15.43	5.68±2.96	37.2±10.8	46.1±12.3	74.3±23.8
t值		4.702	2.825	15.081	10.242	11.351
P值		0.000 6	0.008 0	0.000 0	0.000 0	0.000 0
组别	ALP/（U/L）	TB/（μmol/L）	DBil/（μmol/L）	IgG/（g/L）	IgM/（g/L）	IgA/（g/L）
治疗前	179.4±31.8	97.5±26.8	71.4±22.6	19.9±5.2	7.9±1.9	4.5±2.7
治疗后	94.1±25.8	24.3±8.1	18.4±8.9	8.6±3.7	4.3±2.1	2.8±1.5
t值	7.109	12.450	10.258	7.159	2.928	3.952
P值	0.000 0	0.000 0	0.000 0	0.000 0	0.007 0	0.000 0